Usefulness of radium-223 in patients with bone metastases.

Nishant Gupta Arushi Devgan Itisha Bansal Thomas D Olsavsky Shuo Li Ahmed Abdelbaki Yogesh Kumar

Proc (Bayl Univ Med Cent)

Department of Radiology, Columbia University Medical Center, New York, New York (Gupta); Department of Radiology, University of Arkansas, Little Rock, Arkansas (Devgan); Department of Anesthesiology, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York (Bansal); Department of Nuclear Medicine, St. Vincent's Medical Center, Bridgeport, Connecticut (Olsavsky); Department of Radiology, Yale New Haven Health at Bridgeport Hospital, Bridgeport, Connecticut (Li, Abdelbaki); and Columbia University at Bassett Healthcare, Cooperstown, New York (Kumar).

Published: October 2017

Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595381	PMC
http://dx.doi.org/10.1080/08998280.2017.11930213	DOI Listing

Publication Analysis

Top Keywords

radium-223 patients

patients bone

bone metastases

metastases castration-resistant

castration-resistant prostate

prostate osseous

osseous metastases

metastases challenging

challenging treat

treat era

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!